Hyaluronan inhibits IL-1β-stimulated collagenase production via down-regulation of phosphorylated p38 in SW-1353 human chondrosarcoma cells

Modern Rheumatology

Volumn 18, Issue 3, 2008, Pages 263-270

  Julovi, Sohel M ^a   Ito, Hiromu ^a   Hiramitsu, Teruko ^a   Yasuda, Tadashi ^b   Nakamura, Takashi ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TENRI UNIVERSITY   (Japan)

Author keywords

CD44; Collagenase; Hyaluronan; Interleukin 1 ; p38

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; COLLAGENASE; COLLAGENASE 3; HERMES ANTIGEN; HYALURONIC ACID; INTERLEUKIN 1BETA; INTERSTITIAL COLLAGENASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR;

ARTICLE; CHONDROSARCOMA; CONTROLLED STUDY; CYTOCHEMISTRY; DOWN REGULATION; ENZYME PHOSPHORYLATION; ENZYME SYNTHESIS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; PRIORITY JOURNAL; TUMOR CELL LINE;

ANTIGENS, CD44; CELL LINE, TUMOR; CHONDROSARCOMA; COLLAGENASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; HUMANS; HYALURONIC ACID; INTERLEUKIN-1BETA; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 13; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION;

EID: 46549088304     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-008-0067-7     Document Type: Article

References (33)

1. Goldberg VM, Buckwalter JA. Hyaluronans in the treatment of osteoarthritis of the knee: Evidence for disease-modifying activity. Osteoarthr Cartil. 2005;13(3):216-24.
2. Julovi SM, Yasuda T, Shimizu M, Hiramitsu T, Nakamura T. Inhibition of interleukin-1 βstimulated production of matrix metalloproteinases by hyaluronan via CD44 in human articular cartilage. Arthritis Rheum. 2004;50(2):516-25.
3. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell. 1990;61(7):1303-13.
4. Jeffery J. Interstitial collagenases. In: Parks WC, Mecham RP (eds) Matrix metalloproteinases. San Diego: Academic Press; 1998. p. 15-38.
5. Shlopov BV, Lie WR, Mainardi CL, Cole AA, Chubinskaya S, Hasty KA. Osteoarthritic lesions: Involvement of three different collagenases. Arthritis Rheum. 1997;40(11):2065-74.
6. Knäuper V, Cowell S, Smith B, Lopez-Otin C, O'Shea M, Morris H, et al. The role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction. J Biol Chem. 1997;272(12):7608-16.
7. Tetlow LC, Adlam DJ, Woolley DE. Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage. Associations with degenerative changes. Arthritis Rheum. 2001;44(3):585-94.
8. Geng Y, Valbracht J, Lotz M. Selective activation of mitogen-activated protein kinase subgroups c-Jun NH2 terminal kinase and p38 by IL-1 and TNF in human articular chondrocytes. J Clin Invest. 1996;98(10):2425-30.
9. Shikhman AR, Kuhn K, Alaaeddine NM, Lotz M. N-acetylglucosamine prevents IL-1-mediated activation of human chondrocytes. J Immunol. 2001;166(8):5155-60.
10. Mengshol JA, Vincenti MP, Coon CI, Barchowsky A, Brinckerhoff CE. Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor kappaB: Differential regulation of collagenase 1 and collagenase 3. Arthritis Rheum. 2000;43(4):801-11.
11. Eder J. Tumor necrosis factorα and interleukin 1 signalling: Do MAPKK kinases connect it all? Trends Pharmacol Sci. 1997;18(9):319-22.
12. Vincenti MP, Brinckerhoff CE. The potential of signal transduction inhibitors for the treatment of arthritis: Is it all just JNK? J Clin Invest. 2001;108(2):181-3.
13. Rutter JL, Benbow U, Coon CI, Brinckerhoff CE. Cell-type specific regulation of human interstitial collagense-1 gene expression by interleukin-1β (IL-1β) in human fibroblasts and BC-8701 breast cancer cells. J Cell Biochem. 1997;66(3):322-36.
14. Pendas AM, Balbin M, Llano E, Jiménez MG, López-Otín C. Structural analysis and promoter characterization of human collagenase-3 gene (MMP-13). Genomics. 1997;40(2):222-33.
15. Yasuda T, Julovi SM, Hiramitsu T, Yoshida M, Nakamura T. Requirement of mitogen-activated protein kinase for collagenase production by fibronectin fragment in human articular chondrocytes in culture. Mod Rheumatol. 2004;14(1):54-60.
16. Shimizu M, Yasuda T, Nakagawa T, Yamashita E, Julovi SM, Hiramitsu T, et al. Hyaluronan inhibits matrix metalloproteinase-1 production by rheumatoid synovial fibroblasts stimulated by proinflammatory cytokines. J Rheumatol. 2003;30(6):1164-72.
17. Labarca C, Paigen K. A simple, rapid, and sensitive DNA assay procedure. Anal Biochem. 1980;102(2):344-52.
18. Dahl LB, Dahl IM, Laurent AE, Granath K. Concentration and molecular weight of sodium hyaluronate in synovial fluid from patients with rheumatoid arthritis and other arthropathies. Ann Rheum Dis. 1985;44(12):817-22.
19. Bonassar LJ, Frank EH, Murray JC, Paguio CG, Moore VL, Lark MW, et al. Changes in cartilage composition and physical properties due to stromelysin degradation. Arthritis Rheum. 1995;38(2):173-83.
20. Kempson GE. Mechanical properties of articular cartilage. In: Freeman MAR (ed) Adult articular cartilage. Tunbridge Wells: Pitman Medical; 1979. p. 333-414.
21. Fosang AJ, Last K, Knüuper V, Murphy G, Neame PJ. Degradation of cartilage aggrecan by collagenase-3 (MMP-13). FEBS Lett. 1996;380:17-20.
22. Little CB, Meeker CT, Golub SB, Lawlor KE, Farmer PJ, Smith SM, et al. Blocking aggrecanase cleavage in the aggrecan interglobular domain abrogates cartilage erosion and promotes cartilage repair. J Clin Invest. 2007;117(6):1627-36. Epub 2007 May 17.
23. Ridley SH, Sarsfield SJ, Lee JC, Bigg HF, Cawston TE, Taylor DJ, et al. Actions of IL-1 are selectively controlled by p38 mitogen-activated protein kinase: Regulation of prostaglandin H synthase-2, metalloproteinases, and IL-6 at different levels. J Immunol. 1997;158(7):3165-73.
24. Badger AM, Bradbeer JN, Votta B, Lee JC, Adams JL, Griswold DE. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther. 1996;279(3):1453-61.
25. Pei Y, Harvey A, Yu XP, Chandrasekhar S, Thirunavukkarasu K. Differential regulation of cytokine-induced MMP-1 and MMP-13 expression by p38 kinase inhibitors in human chondrosarcoma cells: Potential role of Runx2 in mediating p38 effects. Osteoarthr Cartil. 2006;14(8):749-58.
26. Toba T, Mizusawa N, Tajima G, Horiuchu S. Upregulation of CD44 mRNA expression by interleukin-1β in cultured rabbit articular chondrocytes. J Bone Miner Metab. 1997;15:84-93.
27. Mikecz K, Dennis K, Shi M, Kim JH. Modulation of hyaluronan receptor (CD44) function in vivo in a murine model of rheumatoid arthritis. Arthritis Rheum. 1999;42:659-68.
28. Ohno S, Im HJ, Knudson CB, Knudson W. Hyaluronan oligosaccharide-induced activation of transcription factors in bovine articular chondrocytes. Arthritis Rheum. 2005;52(3):800-9.
29. Ohno S, Im HJ, Knudson CB, Knudson W. Hyaluronan oligosaccharides induce matrix metalloproteinase 13 via transcriptional activation of NFkappaB and p38 MAP kinase in articular chondrocytes. J Biol Chem. 2006;281(26):17952-60.
30. Tanaka M, Masuko-Hongo K, Kato T, Nishioka K, Nakamura H. Suppressive effects of hyaluronan on MMP-1 and RANTES production from chondrocytes. Rheumatol Int. 2006;26(3):185-90.
31. Wang CT, Lin YT, Chiang BL, Lin YH, Hou SM. High molecular weight hyaluronic acid down-regulates the gene expression of osteoarthritis-associated cytokines and enzymes in fibroblast-like synoviocytes from patients with early osteoarthritis. Osteoarthr Cartil. 2006;14(12):1237-47.
32. Yasuda T. Cartilage destruction by matrix degradation products. Mod Rheumatol. 2006;16(4):197-205.
33. Santangelo KS, Johnson AL, Ruppert AS, Bertone AL. Effects of hyaluronan treatment on lipopolysaccharide-challenged fibroblast-like synovial cells. Arthritis Res Ther. 2007;9(1):R1.